Reuters logo
2 months ago
BRIEF-Amgen says FDA accepts sBLA to expand indication for XGEVA
June 19, 2017 / 1:14 PM / 2 months ago

BRIEF-Amgen says FDA accepts sBLA to expand indication for XGEVA

June 19 (Reuters) - Amgen Inc

* FDA accepts Amgen's supplemental biologics license application to expand indication for XGEVA (denosumab) to include multiple myeloma patients

* Amgen Inc - FDA sets PDUFA target action date of Feb. 3, 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below